CA2884859C - Hiv-1 antibody evolution immunogens - Google Patents

Hiv-1 antibody evolution immunogens Download PDF

Info

Publication number
CA2884859C
CA2884859C CA2884859A CA2884859A CA2884859C CA 2884859 C CA2884859 C CA 2884859C CA 2884859 A CA2884859 A CA 2884859A CA 2884859 A CA2884859 A CA 2884859A CA 2884859 C CA2884859 C CA 2884859C
Authority
CA
Canada
Prior art keywords
hiv
seq
sequence defined
envelope protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2884859A
Other languages
English (en)
French (fr)
Other versions
CA2884859A1 (en
Inventor
Barton F. Haynes
Hua-Xin Liao
Rebecca M. Lynch
Tongqing Zhou
Feng Gao
Scott Boyd
George M. Shaw
Beatrice H. Hahn
Thomas B. Kepler
Bette T. Korber
Peter Kwong
John Mascola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
University of Pennsylvania Penn
Los Alamos National Security LLC
Duke University
Leland Stanford Junior University
US Department of Health and Human Services
Original Assignee
Boston University
University of Pennsylvania Penn
Los Alamos National Security LLC
Duke University
Leland Stanford Junior University
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, University of Pennsylvania Penn, Los Alamos National Security LLC, Duke University, Leland Stanford Junior University, US Department of Health and Human Services filed Critical Boston University
Publication of CA2884859A1 publication Critical patent/CA2884859A1/en
Application granted granted Critical
Publication of CA2884859C publication Critical patent/CA2884859C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2884859A 2012-09-12 2013-09-12 Hiv-1 antibody evolution immunogens Active CA2884859C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261700252P 2012-09-12 2012-09-12
US61/700,252 2012-09-12
US201261708466P 2012-10-01 2012-10-01
US61/708,466 2012-10-01
US201361764421P 2013-02-13 2013-02-13
US61/764,421 2013-02-13
PCT/US2013/000210 WO2014042669A1 (en) 2012-09-12 2013-09-12 Antibody evolution immunogens

Publications (2)

Publication Number Publication Date
CA2884859A1 CA2884859A1 (en) 2014-03-20
CA2884859C true CA2884859C (en) 2024-06-18

Family

ID=50278581

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2884859A Active CA2884859C (en) 2012-09-12 2013-09-12 Hiv-1 antibody evolution immunogens

Country Status (7)

Country Link
US (2) US10004800B2 (https=)
EP (1) EP2895500B1 (https=)
JP (1) JP6491095B2 (https=)
CN (1) CN104968671B (https=)
AU (3) AU2013316100B8 (https=)
CA (1) CA2884859C (https=)
WO (1) WO2014042669A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004800B2 (en) 2012-09-12 2018-06-26 Duke University Antibody evolution immunogens
US10149902B2 (en) 2014-03-19 2018-12-11 Duke University Swarm immunization with envelopes from CH505
US10322141B2 (en) 2014-03-31 2019-06-18 Duke University Compositions comprising CH848 envelopes and uses thereof
CA2962938A1 (en) 2014-09-28 2016-03-31 Duke University Compositions comprising ch505 envelopes, and trimers
US20170216426A1 (en) * 2014-09-28 2017-08-03 Duke University Compositions and methods for transient immune response modulation during vaccination
EP3240559A1 (en) * 2014-12-24 2017-11-08 Duke University Compositions comprising ch505 envelopes, and trimers (eight valent hiv-1 composition and methods)
WO2016172070A1 (en) * 2015-04-20 2016-10-27 Duke University Swarm immunization with envelopes from ch505
CA3016327A1 (en) 2016-03-01 2017-09-08 Duke University Compositions comprising hiv envelopes to induce ch235 lineage antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
WO2018218225A1 (en) 2017-05-25 2018-11-29 Duke University Compositions comprising modified hiv envelopes
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
CN114761041A (zh) 2019-07-16 2022-07-15 吉利德科学公司 Hiv疫苗及其制备和使用方法
US12559527B2 (en) 2019-10-23 2026-02-24 Duke University Compositions comprising V2 opt HIV envelopes
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
JP7799706B2 (ja) * 2021-05-05 2026-01-15 レヴェラージェン，インコーポレーテッド 抗体を産生するための組換え非ヒト動物
CN117651486A (zh) * 2021-05-05 2024-03-05 利威瑞健股份有限公司 用于生产抗体的工程改造的非人动物
WO2023064280A2 (en) * 2021-10-11 2023-04-20 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
US20250340598A1 (en) * 2021-10-12 2025-11-06 Duke University Compositions comprising v2 opt hiv envelopes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218817D0 (en) * 2002-08-13 2002-09-18 San Raffaele Centro Fond Pharmaceutical compounds
ATE552266T1 (de) 2004-08-27 2012-04-15 Jackson H M Found Military Med Modifizierte hiv-1-hüllproteine
US20120039923A1 (en) 2004-09-09 2012-02-16 The Henry M. Jackson Foundation Modified HIV-1 Envelope Proteins
JP2006149234A (ja) 2004-11-25 2006-06-15 Japan Science & Technology Agency プライム−ブーストワクチン接種法
CA2704059A1 (en) 2007-10-30 2009-05-07 International Aids Vaccine Initiative Antigen-antibody complexes as hiv-1 vaccines
US8628782B2 (en) 2009-02-26 2014-01-14 The United States Of America, As Represented By The Department Of Health And Human Services Deletion of the beta 20-21 loop in HIV gp120 exposes the CD4 binding site for improved antibody binding and antibody induction
JP2013505256A (ja) 2009-09-17 2013-02-14 サノフィ パストゥール インコーポレイテッド Ｈｉｖ用の免疫学的組成物
WO2011046623A2 (en) 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
CA2850745C (en) 2011-10-03 2022-12-13 Duke University Vaccine
US10004800B2 (en) 2012-09-12 2018-06-26 Duke University Antibody evolution immunogens

Also Published As

Publication number Publication date
WO2014042669A1 (en) 2014-03-20
CA2884859A1 (en) 2014-03-20
AU2020200453A1 (en) 2020-02-13
JP6491095B2 (ja) 2019-04-03
CN104968671A (zh) 2015-10-07
EP2895500A1 (en) 2015-07-22
US10004800B2 (en) 2018-06-26
CN104968671B (zh) 2020-07-03
JP2015529678A (ja) 2015-10-08
US10849970B2 (en) 2020-12-01
EP2895500A4 (en) 2016-04-13
AU2013316100B2 (en) 2018-03-01
AU2013316100B8 (en) 2018-03-08
EP2895500B1 (en) 2019-11-27
US20180360948A1 (en) 2018-12-20
US20150366961A1 (en) 2015-12-24
AU2018203805A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
CA2884859C (en) Hiv-1 antibody evolution immunogens
Liao et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Gorman et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design
US11248027B2 (en) Engineered outer domain (eOD) of HIV GP120, mutants and use thereof
US9988424B2 (en) Immunogens comprising human immunodeficiency virus V1/V2 polypeptides
US20210277065A1 (en) Compositions comprising hiv envelopes to induce ch235 lineage antibodies
WO2016149710A2 (en) Hiv-1 neutralizing antibodies and uses thereof
US20200199204A1 (en) Broadly Neutralizing Monoclonal Antibodies Against HIV-1 V1V2 Env Region
US10273291B2 (en) Focused evolution of HIV-1 neutralizing antibodies revealed by crystal structures and deep sequencing
Gong et al. Candidate antibody-based therapeutics against HIV-1
WO2018053328A1 (en) Bispecific molecules comprising an hiv-1 envelope targeting arm
US20220096632A1 (en) Hiv-1 neutralizing antibodies and uses thereof
WO2025151836A1 (en) Antibodies against sarbecoviruses, their variants and uses thereof
HK40046504A (en) Broadly neutralizing monoclonal antibodies against hiv-1 v1v2 env region
Bhiman Defining Virus-Antibody Interplay During the Development of HIV-1 Neutralization Breadth to Inform Vaccine Design

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180907

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250905

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250905